文献速递肝病

代谢功能障碍相关脂肪性肝炎全球临床、人文与经济影响预测:九国不作为代价

Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-09-08

本研究采用1年周期马尔可夫模型,基于2020年患病数据和2021—2040年发病数据,预测九国MASH进展。结果显示各国MASH患病率均上升,晚期MASH患病率预计增加≥20%,直接医疗费用在多数国家翻倍以上, productivity损失和健康相关生活质量下降。结论强调需国家和全球策略以减轻MASH负担。

要点

  • 2021—2040年九国MASH患病率均上升,美国从6.71%升至7.41%。
  • 所有国家晚期MASH(F3-肝硬化、失代偿肝硬化、HCC、肝移植)患病率预计增加≥20%。

核心结论

  • 若不干预,多数地区MASH的临床、经济和生活质量负担预计将增加。
  • 研究结果强调需要国家和全球策略以减少MASH对个人和社会的负面影响。

研究设计与样本

  • 采用1年周期马尔可夫模型预测2021至2040年MASH进展。
  • 模型纳入2020年患病病例和2021—2040年年发病病例。
  • 转移概率来自文献,并使用各国2型糖尿病和肥胖患病率估计进行校准,同时根据观察到的失代偿肝硬化、肝细胞癌和肝移植发病率进行调整。
  • MASH相关直接费用、生产力损失和生活质量根据预测疾病阶段每年更新。
  • 未来经济负担使用国际货币基金组织提供的各国通胀率进行调整。

主要发现

  • MASH患病率(2021—2040年)预计增加:美国6.71%—7.41%,德国4.43%—4.97%,西班牙4.50%—5.38%,法国4.04%—4.50%,意大利4.58%—5.37%,英国4.75%—5.21%,日本3.67%—5.02%,巴西7.19%—7.52%,沙特阿拉伯7.39%—7.50%。
  • 所有国家晚期MASH(F3-代偿性肝硬化、失代偿性肝硬化、肝细胞癌和肝移植)患病率预计增加≥20%。
  • 大多数国家工作生产力损失预计翻倍以上,随着晚期疾病负担增加,健康相关生活质量将适度下降。

临床怎么用

  • 临床医生应认识到MASH负担预计持续增加,需加强早期识别和干预以延缓疾病进展。
  • 卫生系统应规划资源以应对MASH相关直接医疗费用和生产力损失的显著上升。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although the clinical burden of metabolic dysfunction-associated steatohepatitis (MASH) is well-known, its economic burden is less well-described. We estimated MASH's economic burden in several regions of the world including the United States (U.S.), Germany, Spain, France, Italy, the United Kingdom (UK), Japan, Saudi Arabia, and Brazil over the next 2 decades. METHODS: A 1-year cycle Markov model projected MASH progression from 2021 to 2040, incorporating 2020 prevalent cases and annual incident cases (2021-2040). Transition probabilities were derived from the literature, calibrated using national estimates of prevalence rates for type 2 diabetes and obesity, and adjusted against observed incidences of decompensated cirrhosis, hepatocellular carcinoma, and liver transplants. MASH-related direct costs, productivity losses, and quality-of-life were updated annually based on projected disease stage. Future economic burdens were adjusted using country-specific inflation rates from the International Monetary Fund. RESULTS: MASH prevalence is projected to increase (2021-2040): United States (6.71%-7.41%), Germany (4.43%-4.97%), Spain (4.50%-5.38%), France (4.04%-4.50%), Italy (4.58%-5.37%), United Kingdom (4.75%-5.21%), Japan (3.67%-5.02%), Brazil (7.19%-7.52%), and Saudi Arabia (7.39%-7.50%). The prevalence of advanced MASH (F3- compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and liver transplantations) is expected to increase by ≥20% in all countries. Direct annual medical costs are projected to more than double, increasing from $34.97 to $78.59 billion in the United States, $0.83 to $1.82 billion in Germany, $1.48 to $3.50 billion in Spain, $1.28 to $2.90 billion in France, $1.34 to $3.00 billion in Italy, $2.18 to $5.29 billion in the United Kingdom, $1.20 to $2.33 billion in Japan, $3.41 to $9.81 billion in Brazil, and $1.72 to $3.96 billion in Saudi Arabia. Work productivity losses are projected to more than double in most countries, and health-related quality of life will decline modestly as the burden of advanced disease increases CONCLUSIONS: Without intervention, the clinical, economic, and quality-of-life burden of MASH is projected to increase across most regions of the world. These findings highlight the urgent need for both national and global strategies to reduce the negative impact of MASH on individuals and society.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Paik JM, Lazarus JV, et al. Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries. Clin Gastroenterol Hepatol. 2025. PMID: 40930305. doi:10.1016/j.cgh.2025.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。